AstraZeneca – Recall of Brilinta® (ticagrelor)
May 26, 2017 – the FDA announced a voluntary, consumer-level recall of one lot of AstraZeneca's Brilinta (ticagrelor) 90 mg tablets, due to a report that a professional sample bottle containing eight tablets of Brilinta 90 mg also contained another medicine called Zurampic® (lesinurad) 200 mg tablets.
Top